Abstract:Metabolic reprogramming is a hallmark of cancer cells and a key contributor to cancer progression, which is a promising target for cancer therapies. The enhanced glycolysis, also known as the Warburg effect, represents the most widely recognized metabolic alteration in cancer, wherein the majority of cancer cells undergoes reprogramming to heavily rely on glycolysis for their accelerated growth and proliferation. The glycolytic enzyme lactate dehydrogenase A (LDHA) catalyzes the conversion of pyruvate to lactate in the final stage of glycolysis. LDHA is frequently overexpressed in cancers, which plays a critical role in promoting glycolysis and cancer progression. To deepen our understanding of the oncogenic mechanism of LDHA, we screened for LDHA-interacting proteins in human breast cancer cells by liquid chromatography mass spectrometry (LC/MS) analysis. Through this strategy, small GTPase Rac1 was identified as an LDHA-interacting protein. LDHA interacted with the active form of Rac1, Rac1-GTP, and impaired the interaction of Rac1-GTP with its negative regulators, GTPase-activating proteins, leading to Rac1 activation independently of the glycolytic enzyme activity of LDHA. In addition, LDHA overexpression was significantly associated with increased Rac1 activity in clinical breast cancer specimens. Inhibiting Rac1 significantly attenuated the oncogenic effect of LDHA. Combining small-molecule inhibitors targeting LDHA enzyme activity and Rac1 activity displayed a synergistic inhibitory effect on breast cancers with LDHA overexpression in mouse models. Thus, our results revealed a novel and critical noncanonical mechanism of LDHA in promoting cancer progression through its direct interaction and activation of Rac1. Given that LDHA is frequently overexpressed in cancer, LDHA overexpression constitutes an important mechanism contributing to aberrant Rac1 activation in cancer. Importantly, our findings also suggest that pharmacologically targeting LDHA enzyme activity and Rac1 activity simultaneously is a promising strategy to treat breast cancers with LDHA overexpression. Citation Format: Juan Liu, Wenwei Hu, Zhaohui Feng. The noncanonical mechanism of metabolic enzyme LDHA in cancer progression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 432.

Structural basis of lactate dehydrogenase A-gossypol complex

Structural identification and comprehension of human ALDH1L1-Gossypol complex

Structural Evidence for Isoform-Selective Allosteric Inhibition of Lactate Dehydrogenase A

Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy

Synthesis and initial screening of lactate dehydrogenase inhibitor activity of 1,3-benzodioxole derivatives

Design, Synthesis and Structure-Activity Relationship Studies of Glycosylated Derivatives of Marine Natural Product Lamellarin D

Lactate dehydrogenase a in cancer: A promising target for diagnosis and therapy

Development of human lactate dehydrogenase a inhibitors: high-throughput screening, molecular dynamics simulation and enzyme activity assay

Structure-based optimization of hydroxylactam as potent, cell-active inhibitors of lactate dehydrogenase

Identification of dihydroorotate dehydrogenase as a protein target of ginkgolic acid by molecular docking and dynamics

Natural compounds as lactate dehydrogenase inhibitors: potential therapeutics for lactate dehydrogenase inhibitors-related diseases

Exploring the possibility of drug repurposing for cancer therapy targeting human lactate dehydrogenase A: a computational approach

Structural basis for 18-β-glycyrrhetinic acid as a novel non-GSH analog glyoxalase I inhibitor

LDHA: The Obstacle to T cell responses against tumor

Mapping the binding site for gossypol-like inhibitors of Plasmodium falciparum lactate dehydrogenase

Prevention and treatment of bleomycin-induced pulmonary fibrosis with the lactate dehydrogenase inhibitor gossypol

Dual inhibitory potential of ganoderic acid A on GLUT1/3: computational and in vitro insights into targeting glucose metabolism in human lung cancer

Dissecting the Structure–Activity Relationship of Galectin–Ligand Interactions

Abstract 432: The noncanonical mechanism of metabolic enzyme LDHA in cancer progression

Natural product 1,2,3,4,6-penta-O-galloyl-β-D-glucopyranose is a reversible inhibitor of glyceraldehyde 3-phosphate dehydrogenase

Recombinant Production and Biochemical and in Silico Characterization of Lactate Dehydrogenase from Geobacillus Thermodenitrificans DSM-465